PIVKA-II Total

PIVKA-II total typically includes tests related to liver function and tumour markers. It encompasses the Liver Function Profile, which assesses enzymes and proteins produced by the liver. Des-gamma-carboxy prothrombin (DCP), also known as PIVKA-II, and Alpha-Fetoprotein (AFP) are tumour markers included to help detect and monitor liver cancer, particularly hepatocellular carcinoma (HCC). This panel aids in both liver disease assessment and cancer diagnosis.

Why consider PIVKA Total test?

The PIVKA-II Total test is recommended for assessing liver health and detecting liver cancer, particularly hepatocellular carcinoma (HCC). It includes Liver Function Tests, Des-gamma-carboxy prothrombin (PIVKA-II), and Alpha-Fetoprotein (AFP). PIVKA-II and AFP are important tumor markers that help in early diagnosis and monitoring of liver cancer. This test is especially useful for individuals with chronic liver disease or at high risk for HCC. Early detection through this panel can improve treatment outcomes.

Who should get PIVKA Total test done?

• Individuals with chronic liver diseases like hepatitis B or C.
• Those with a family history of liver cancer.
• Patients with cirrhosis or liver damage from alcohol or fatty liver disease.
• People under regular surveillance for hepatocellular carcinoma (HCC).
• Anyone with abnormal liver function tests or symptoms suggesting liver issues.

More Information about PIVKA Total test

The PIVKA-II Total test can support early intervention by identifying liver cancer before symptoms appear. It’s particularly useful when imaging is inconclusive. Regular testing in high-risk patients can improve long-term outcomes through timely treatment.

Other Names: DCP Test, PIVKA-II with AFP Panel